OBJECTIVE: Saphenous vein grafts suffer from neointima formation following bypass surgery. Matrix metalloproteinases (MMPs) play important roles in this process. We examined MMP-3 for its therapeutic potential to prevent smooth muscle cell migration and neointima formation in venous bypass grafts using adenovirus-mediated gene transfer. METHODS: Human aortic smooth muscle cells (HASMC) were transduced with adenoviral vectors encoding ss-galactosidase (Ad.ssgal) [corrected] or human MMP-3 (Ad.hMMP-(3)), [corrected] and characterized for migration in the amniotic membrane stroma as an in vitro model of the vascular wall. Cholesterol-fed New Zealand white rabbits underwent jugular vein bypass grafting into carotid arteries. Before insertion, grafts were incubated ex vivo with either Ad.ssgal [corrected] or hMMP-3. Transgene expression was characterized by immunohistochemistry and in situ zymography. Grafts (n = 6) were explanted after 28 days and intimal hyperplasia was quantified. RESULTS: Migration of HASMC was significantly reduced when transduced with Ad.hMMP-(3) [corrected] compared to controls (P < .001). Immunocytochemistry of Ad.hMMP-(3) [corrected] transduced venous grafts localized this protein to the intima. In situ-zymography showed increased MMP activity in the intima of Ad.hMMP-(3) [corrected] transfected grafts. Stenosis degree (P = .001), intima/media-ratio (P = .023) and lesion thickness (P = .003) were significantly reduced in grafts transduced with Ad.MMP-3 in comparison to controls. There was no difference inside control groups. CONCLUSION: MMP-3 overexpression inhibits formation of intimal hyperplasia in arterialized vein grafts. Adenovirus mediated gene transfer of MMP-3 may be of clinical use to prevent vein graft stenosis following bypass surgery.
OBJECTIVE: Saphenous vein grafts suffer from neointima formation following bypass surgery. Matrix metalloproteinases (MMPs) play important roles in this process. We examined MMP-3 for its therapeutic potential to prevent smooth muscle cell migration and neointima formation in venous bypass grafts using adenovirus-mediated gene transfer. METHODS:Human aortic smooth muscle cells (HASMC) were transduced with adenoviral vectors encoding ss-galactosidase (Ad.ssgal) [corrected] or humanMMP-3 (Ad.hMMP-(3)), [corrected] and characterized for migration in the amniotic membrane stroma as an in vitro model of the vascular wall. Cholesterol-fed New Zealand white rabbits underwent jugular vein bypass grafting into carotid arteries. Before insertion, grafts were incubated ex vivo with either Ad.ssgal [corrected] or hMMP-3. Transgene expression was characterized by immunohistochemistry and in situ zymography. Grafts (n = 6) were explanted after 28 days and intimal hyperplasia was quantified. RESULTS: Migration of HASMC was significantly reduced when transduced with Ad.hMMP-(3) [corrected] compared to controls (P < .001). Immunocytochemistry of Ad.hMMP-(3) [corrected] transduced venous grafts localized this protein to the intima. In situ-zymography showed increased MMP activity in the intima of Ad.hMMP-(3) [corrected] transfected grafts. Stenosis degree (P = .001), intima/media-ratio (P = .023) and lesion thickness (P = .003) were significantly reduced in grafts transduced with Ad.MMP-3 in comparison to controls. There was no difference inside control groups. CONCLUSION:MMP-3 overexpression inhibits formation of intimal hyperplasia in arterialized vein grafts. Adenovirus mediated gene transfer of MMP-3 may be of clinical use to prevent vein graft stenosis following bypass surgery.
Authors: H Haro; H C Crawford; B Fingleton; J R MacDougall; K Shinomiya; D M Spengler; L M Matrisian Journal: J Clin Invest Date: 2000-01 Impact factor: 14.808
Authors: Klaus Kallenbach; Harold A Fernandez; Graziano Seghezzi; F Gregory Baumann; Sundeep Patel; Eugene A Grossi; Aubrey C Galloway; Paolo Mignatti Journal: Arterioscler Thromb Vasc Biol Date: 2003-04-03 Impact factor: 8.311
Authors: A Gnasso; C Motti; C Irace; C Carallo; L Liberatoscioli; S Bernardini; R Massoud; P L Mattioli; G Federici; C Cortese Journal: Arterioscler Thromb Vasc Biol Date: 2000-06 Impact factor: 8.311
Authors: K Bajou; A Noël; R D Gerard; V Masson; N Brunner; C Holst-Hansen; M Skobe; N E Fusenig; P Carmeliet; D Collen; J M Foidart Journal: Nat Med Date: 1998-08 Impact factor: 53.440
Authors: Tracy L Adair-Kirk; Jeffrey J Atkinson; Thomas J Broekelmann; Masayuki Doi; Karl Tryggvason; Jeffrey H Miner; Robert P Mecham; Robert M Senior Journal: J Immunol Date: 2003-07-01 Impact factor: 5.422
Authors: Giuseppe Pintucci; Pey-Jen Yu; Ram Sharony; F Gregory Baumann; Fiorella Saponara; Antonio Frasca; Aubrey C Galloway; David Moscatelli; Paolo Mignatti Journal: J Cell Biochem Date: 2003-12-01 Impact factor: 4.429
Authors: K Bajou; V Masson; R D Gerard; P M Schmitt; V Albert; M Praus; L R Lund; T L Frandsen; N Brunner; K Dano; N E Fusenig; U Weidle; G Carmeliet; D Loskutoff; D Collen; P Carmeliet; J M Foidart; A Noël Journal: J Cell Biol Date: 2001-02-19 Impact factor: 10.539
Authors: Zhihua Jiang; Ming Tao; Kerri A Omalley; Danlu Wang; C Keith Ozaki; Scott A Berceli Journal: Am J Physiol Heart Circ Physiol Date: 2009-07-17 Impact factor: 4.733
Authors: Anna V Piterina; Aidan J Cloonan; Claire L Meaney; Laura M Davis; Anthony Callanan; Michael T Walsh; Tim M McGloughlin Journal: Int J Mol Sci Date: 2009-11-20 Impact factor: 6.208
Authors: Philipp Christian Seppelt; Simon Schwill; Alexander Weymann; Rawa Arif; Antje Weber; Marcin Zaradzki; Karsten Richter; Stephan Ensminger; Peter Nicholas Robinson; Andreas H Wagner; Matthias Karck; Klaus Kallenbach Journal: PLoS One Date: 2016-02-03 Impact factor: 3.240